Similarly, an IgG1 version of the anti-CD47 antibody is expected to possess antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity against GBM. This evidence concerns the gene CD47 and glioblastoma.